Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F., Miller, W.H., Oh, D.-Y., Gottfried, M., Xu, L., Jin, F., Norwood, K., Marabelle, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study
Cassier, P.A., Kantor, G., Bonvalot, S., Lavergne, E., Stoeckle, E., Le Péchoux, C., Meeus, P., Sunyach, M.-P., Vaz, G., Coindre, J.-M., Linassier, C., Labib, A., Delcambre, C., Bay, J.-O., Leyvraz, S., Dubergé, T., Lagrange, J.-L., Duret, A., Blay, J.-Y.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
Gomez-Roca, C.A., Italiano, A., Le Tourneau, C., Cassier, P.A., Toulmonde, M., D’Angelo, S.P., Campone, M., Weber, K.L., Loirat, D., Cannarile, M.A., Jegg, A.-M., Ries, C., Christen, R., Meneses-Lorente, G., Jacob, W., Klaman, I., Ooi, C.-H., Watson, C., Wonde, K., Reis, B., Michielin, F., Rüttinger, D., Delord, J.-P., Blay, J.-Y.
Published in Annals of oncology (01.08.2019)
Published in Annals of oncology (01.08.2019)
Get full text
Journal Article
1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors
Akerley, W., Reilley, M., Marabelle, A., Baldini, C., Cassier, P.A., Chisamore, M., Tang, T., Lautermilch, N., Hong, D.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
486P Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
Cassier, P.A., Bendjama, K., Garcia, V. Moreno, De Speville Uribe, B. Doger, Calvo, E., de Miguel, M.J., Jungels, C., Erbs, P., Carpentier, D., Sadoun, A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
Negrao, M.V., Cassier, P.A., Solomon, B., Schuler, M., Rohrberg, K., Cresta, S., Dooms, C., Tan, D.S.W., Loong, H.H-f., Amatu, A., Assmann, K. Krueger, Fairchild, L., Sansregret, L., Fan, L., Farago, A.F., Cho, B.C.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
Maio, M., Ascierto, P.A., Motola Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus-Acosta, A., Doi, T., Longo Muñoz, F., Miller, W.H., Oh, D-Y., Gottfried, M., Yao, L., Jin, F.J., Gozman, A., Marabelle, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus-Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Yao, L., Gozman, A., Jin, F.J., Maio, M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
Moreno Garcia, V., Cassier, P.A., Doger de Spéville, B., Calvo, E., De Miguel, M.J., Garcia-Carbonero, R., Gomez-Roca, C.A., Jungels, C., P. Erbs, Sainte-Croix, S., Sadoun, A., Bendjama, K.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Patients’ selection and trial matching in early-phase oncology clinical trials
Corbaux, P., Bayle, A., Besle, S., Vinceneux, A., Vanacker, H., Ouali, K., Hanvic, B., Baldini, C., Cassier, P.A., Terret, C., Verlingue, L.
Published in Critical reviews in oncology/hematology (01.04.2024)
Published in Critical reviews in oncology/hematology (01.04.2024)
Get full text
Journal Article
797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158
O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Amonkar, M., Xu, L., Jin, F., Norwood, K., Maio, M.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Kotecki, N., Champiat, S., Delord, J-P., Vinceneux, A., Jungels, C., Marabelle, A., Korakis, I., Wojciekowski, S., Block, E., Clarke, N., Fromond, C., Poirier, N., Costantini, D., Vasseur, B., Cassier, P.A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Xu, L., Jin, F., Norwood, K., Maio, M.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers
Vanacker, H., Cassier, P.A., Pérol, M., Saintigny, P., Eberst, L., Carbonnaux, M., Brahmi, M., Verlingue, L., Ray-Coquard, I.L., Pérol, D., Blay, J-Y
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Hollebecque, A., Borad, M., Goyal, L., Schram, A., Park, J.O., Cassier, P.A., Kamath, S.D., Meng, D.T. Wai, Dotan, E., Kim, R., Sahai, V., Oh, D-Y., Liao, C-Y., Millward, M., Perez, D. Roda, Ferté, C., Blakesley, R., Wolf, B., Subbiah, V., Kelley, R.K.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
Postel-Vinay, S., Italiano, A., Martin Romano, P., Cassier, P.A., Siu, L.L., Lossos, I.S., Hilton, J.F., Mckean, M.A., Strauss, J., Falchook, G.S., de Jonge, M.J.A., Opdam, F.L., Rasco, D., Vermaat, J.S., Crossman, T., Zajac, M., Hainline, A., Kremer, B., Barbash, O., Gounder, M.M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)
Cassier, P.A., Terret, C., Voisin, A., Schiffler, C., Bidaux, A-S., Vanacker, H., Eberst, L., Lepercq, M.W., D'Argenio, A., M. Bernardin, Bouhamama, A., Gilles-Afchain, L., Treilleux, I., Tabone-Eglinger, S., Spaggiari, D., Chabaud, S., Grinberg-Bleyer, Y., Garin, G., Perol, D., Vinceneux, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
Hu, M.I., Subbiah, V., Mansfield, A.S., Taylor, M., Schuler, M.H.H., Zhu, V., Hadoux, J., Curigliano, G., Wirth, L.J., Garralda, E., Adkins, D.R., Godbert, Y., Ahn, M-J., Cassier, P.A., Cho, B.C., Lin, C-C., Barata, T., Zalutskaya, A., Scalori, A., Brose, M.S.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article